TenNor Therapeutics files first post-listing monthly return; share count steady at 52.33 million and public float compliant

Bulletin Express06-02

TenNor Therapeutics (Suzhou) Limited released its inaugural Monthly Return on Movements in Securities for the period ended 31 May 2026, covering the first full month after its Main Board debut on 22 May 2026.

Authorised and issued capital • Authorised/registered share capital stood at 52.33 million ordinary H shares with a par value of RMB1 each, equal to RMB 52.33 million. • No changes were recorded during the month; the authorised and issued share counts remained identical to the balance at listing.

Issued shares and public float • Total issued shares (excluding treasury shares) were unchanged at 52.33 million. • The company held no treasury shares. • Management confirmed compliance with the Main Board’s 25 per cent minimum public-float requirement.

Corporate actions • The filing reported no share options, warrants, convertible instruments or other agreements that could dilute the share base. • There were no repurchases, cancellations, or other movements in issued or treasury shares.

Governance statement The return was authorised by Ma Zhenkun, Chairman, Executive Director, Chief Executive Officer and General Manager of TenNor Therapeutics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186022702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186022702","market":"hk","top_or_hot":-1,"title":"TenNor Therapeutics files first post-listing monthly return; share count steady at 52.33 million and public float compliant","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited released its inaugural Monthly Return on Movements in Securities for the period ended 31 May 2026, covering the first full month after its Main Board debut on 22 May 2026.</p>\n<p>Authorised and issued capital  \n• Authorised/registered share capital stood at 52.33 million ordinary H shares with a par value of RMB1 each, equal to RMB 52.33 million.  \n• No changes were recorded during the month; the authorised and issued share counts remained identical to the balance at listing.</p>\n<p>Issued shares and public float  \n• Total issued shares (excluding treasury shares) were unchanged at 52.33 million.  \n• The company held no treasury shares.  \n• Management confirmed compliance with the Main Board’s 25 per cent minimum public-float requirement.</p>\n<p>Corporate actions  \n• The filing reported no share options, warrants, convertible instruments or other agreements that could dilute the share base.  \n• There were no repurchases, cancellations, or other movements in issued or treasury shares.</p>\n<p>Governance statement  \nThe return was authorised by Ma Zhenkun, Chairman, Executive Director, Chief Executive Officer and General Manager of TenNor Therapeutics.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics files first post-listing monthly return; share count steady at 52.33 million and public float compliant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics files first post-listing monthly return; share count steady at 52.33 million and public float compliant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited released its inaugural Monthly Return on Movements in Securities for the period ended 31 May 2026, covering the first full month after its Main Board debut on 22 May 2026.</p>\n<p>Authorised and issued capital  \n• Authorised/registered share capital stood at 52.33 million ordinary H shares with a par value of RMB1 each, equal to RMB 52.33 million.  \n• No changes were recorded during the month; the authorised and issued share counts remained identical to the balance at listing.</p>\n<p>Issued shares and public float  \n• Total issued shares (excluding treasury shares) were unchanged at 52.33 million.  \n• The company held no treasury shares.  \n• Management confirmed compliance with the Main Board’s 25 per cent minimum public-float requirement.</p>\n<p>Corporate actions  \n• The filing reported no share options, warrants, convertible instruments or other agreements that could dilute the share base.  \n• There were no repurchases, cancellations, or other movements in issued or treasury shares.</p>\n<p>Governance statement  \nThe return was authorised by Ma Zhenkun, Chairman, Executive Director, Chief Executive Officer and General Manager of TenNor Therapeutics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1186022702","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186022702","pubTimestamp":1780399390,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited released its inaugural Monthly Return on Movements in Securities for the period ended 31 May 2026, covering the first full month after its Main Board debut on 22...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics提交首份上市后月度报告；股份数量稳定在5233万股，符合公众持股量","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited released its inaugural Monthly Return on Movements in Securities for the period ended 31 May 2026, covering the first full month after its Main Board debut on 22 May 2026.\nAuthorised and issued capital  \n• Authorised/registered share capital stood at 52.33 million ordinary H shares with a par value of RMB1 each, equal to RMB 52.33 million.  \n• No changes were recorded during the month; the authorised and issued share counts remained identical to the balance at listing.\nIssued shares and public float  \n• Total issued shares (excluding treasury shares) were unchanged at 52.33 million.  \n• The company held no treasury shares.  \n• Management confirmed compliance with the Main Board’s 25 per cent minimum public-float requirement.\nCorporate actions  \n• The filing reported no share options, warrants, convertible instruments or other agreements that could dilute the share base.  \n• There were no repurchases, cancellations, or other movements in issued or treasury shares.\nGovernance statement  \nThe return was authorised by Ma Zhenkun, Chairman, Executive Director, Chief Executive Officer and General Manager of TenNor Therapeutics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186022702","isCrawlerRequest":true}